Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials

著者: Karine Clément, Erica L T van den Akker, Jesús Argente, Allison Bahm, Wendy K Chung, Hillori Connors, Kathleen De Waele, I. Sadaf Farooqi, Julie Gonneau-Lejeune, Gregory Gordon, Katja Kohlsdorf, Christine Poitou, Lia Puder, James Swain, Murray Stewart, Guojun Yuan, Martin Wabitsch, Peter Kühnen, Patricia Pigeon-Kherchiche, Anna Flaus-Furmaniuk, Martin Bald, Christian Denzer, Julia von Schnurbein, Ozair Abawi, Ulrike Blume‐Peytavi, Philipp Krabusch, Knut Mai, Dirk Schnabel, Susanna Wiegand, Christa E. Flück, Esther Schulz, Egbert Voß, Nataša Bratina, Katja Weiß, Gabriel Ángel Martos‐Moreno, Alban Danset, Paul Gougis, Béatrice Dubern, Karine Clément, Erica L T van den Akker, Jesús Argente, Allison Bahm, Wendy K Chung, Hillori Connors, Kathleen De Waele, I. Sadaf Farooqi, Julie Gonneau-Lejeune, Gregory Gordon, Christine Poitou, Lia Puder, James Swain, Murray Stewart, Goujun Yuan, Martin Wabitsch, Peter Kühnen - The Lancet 2020 被引用: 463